Key result
Recombinant human β-cardiac myosin with HCM-causing converter mutations (R719W, R723G, G741R) exhibited similar or slightly hypocontractile biomechanical properties compared to wild type.
Why the study?
Do converter domain mutations in human β-cardiac myosin increase intrinsic force or duty ratio compared to wild type?
Population
Recombinant human β-cardiac myosin
Comparison
Converter domain mutations vs Wild type human β-cardiac myosin
Design
Preclinical
Authors
Loading...
Does not support direct hypercontractility from converter mutations; challenges prior models and leaves open alternative HCM mechanisms.
Do converter domain mutations in human β-cardiac myosin increase intrinsic force or duty ratio compared to wild type?
HCM-causing converter domain mutations in human β-cardiac myosin do not increase intrinsic force, suggesting alternative mechanisms for clinically observed hypercontractility.
Kawana et al. (2017) studied Hypertrophic cardiomyopathy. Recombinant human β-cardiac myosin with converter domain mutations (R719W, R723G, G741R) vs. Wild type myosin was evaluated on Biomechanical properties (intrinsic force, gliding velocity, ATPase activity). Recombinant human β-cardiac myosin with HCM-causing converter mutations (R719W, R723G, G741R) exhibited similar or slightly hypocontractile biomechanical properties compared to wild type.